FIGURE 5.

Induced Tau-YFP aggregates in C17.2 cells are fibrillar and seed MTBR fibrillization in vitro. C17.2 cells, in which Tau-YFP aggregation was induced by treatment with MTBR aggregates, were extracted with Sarkosyl. Scale bars, 0.2 μm. A, insoluble material was visualized by AFM, which demonstrates fibrils. B, Tau5 antibody labeling increases the diameter of the observed fibrils, indicating their principle constituent is Tau-YFP. C, Sarkosyl-extracted Tau-YFP fibrils from aggregate-treated cells were used to seed the fibrillization of recombinant MTBR in vitro. The resultant fibrils were visualized by AFM. D, MTBR fibrils seeded by Tau-YFP were exposed to Tau5 antibody, which labels the Tau-YFP seeds within the MTBR fibrils.